HeartBeam CEO Robert Eno Departs; Strategic Reorganization
HeartBeam, Inc. announced a significant leadership transition and strategic reorganization. Robert P. Eno mutually agreed to depart as CEO, Board member, and principal executive officer, effective June 30, 2026, and is expected to transition to a consulting role. Concurrently, Mark Strome resigned from the Board, effective immediately. The company will now align its operations around focused implementation teams led by Branislav Vajdic, Ph.D., who will also serve as principal executive officer, and Executive Chairman Rich Ferrari. This reorganization is part of a strategic shift to accelerate global adoption of its ambulatory ECG signal platform, focusing on licensing its technology and advancing towards heart attack detection, aiming for a leaner and more capital-efficient structure.
Key Highlights
- Robert P. Eno departed as CEO, Board member, and principal executive officer, effective June 30, 2026.
- Mr. Eno is expected to enter a consulting agreement to provide advisory support services.
- Mark Strome resigned from the Board and all committees, effective immediately.
- Branislav Vajdic, Ph.D., Founder and President, will serve as principal executive officer from July 1, 2026.
- Company operations will be led by focused implementation teams under Dr. Vajdic and Rich Ferrari.
- HeartBeam announced a strategic shift to license its 3D ECG signal technology and focus on heart attack detection.
- The reorganization aims for global market reach, capital efficiency, and a meaningfully lower cost structure.
- FDA marketing clearance for its synthesized 12-lead ECG signal for arrhythmia assessment was received in December 2025.
Price Impact
More from BEAT